Potentiation strategies of dendritic cell-based antitumor vaccines: Combinational therapy takes the front seat

Drug Discovery Today

Volumn 16, Issue 15-16, 2011, Pages 733-740

  Torabi Rahvar, Monireh ^a   Bozorgmehr, Mahmood ^b   Jeddi Tehrani, Mahmood ^b   Zarnani, Amir Hassan ^a,b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b AVICENNA RESEARCH INSTITUTE   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ANTIBODY; CD40 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENDRITIC CELL VACCINE; INDOLEAMINE 2,3 DIOXYGENASE; TOLL LIKE RECEPTOR; VASCULOTROPIN;

BACTERIUM CULTURE; CANCER IMMUNOTHERAPY; CELL ACTIVATION; CELL MATURATION; CELL PROLIFERATION; DENDRITIC CELL; DRUG POTENTIATION; ENZYME INHIBITION; IN VITRO STUDY; LISTERIA; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CANCER VACCINES; DENDRITIC CELLS; DRUG DESIGN; HUMANS; IMMUNE SYSTEM; IMMUNOTHERAPY; NEOPLASMS;

EID: 80051663961     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2011.04.010     Document Type: Review

References (93)

1. C.A. Power Cloning and characterization of a specific receptor for the novel CC chemokine MIP-3alpha from lung dendritic cells J. Exp. Med. 186 1997 825 835 (Pubitemid 27407344)
2. A. Iwasaki, and B.L. Kelsall Freshly isolated Peyer's patch, but not spleen, dendritic cells produce interleukin 10 and induce the differentiation of T helper type 2 cells J. Exp. Med. 190 1999 229 239 (Pubitemid 29354916)
3. K. Matsuno A life stage of particle-laden rat dendritic cells in vivo: their terminal division, active phagocytosis, and translocation from the liver to the draining lymph J. Exp. Med. 183 1996 1865 1878 (Pubitemid 26134327)
4. F.O. Nestle Characterization of dermal dendritic cells in psoriasis. Autostimulation of T lymphocytes and induction of Th1 type cytokines J. Clin. Invest. 94 1994 202 209
5. D. Vremec, and K. Shortman Dendritic cell subtypes in mouse lymphoid organs: cross-correlation of surface markers, changes with incubation, and differences among thymus, spleen, and lymph nodes J. Immunol. 159 1997 565 573 (Pubitemid 127484204)
6. A.H. Zarnani The efficient isolation of murine splenic dendritic cells and their cytochemical features Histochem. Cell. Biol. 126 2006 275 282
7. A.H. Zarnani Analysis of endometrial myeloid and lymphoid dendritic cells during mouse estrous cycle J. Reprod. Immunol. 71 2006 28 40
8. A.H. Zarnani Kinetics of murine decidual dendritic cells Reproduction 133 2007 275 283
9. J. Banchereau Immunobiology of dendritic cells Annu. Rev. Immunol. 18 2000 767 811 (Pubitemid 30365397)
10. J. Shojaeian Immunosuppressive effect of pregnant mouse serum on allostimulatory activity of dendritic cells J. Reprod. Immunol. 75 2007 23 31 (Pubitemid 47081186)
11. A.H. Zarnani Microenvironment of the feto-maternal interface protects the semiallogenic fetus through its immunomodulatory activity on dendritic cells Fertil. Steril. 90 2008 781 788
12. S. Mocellin Cytokines and immune response in the tumor microenvironment J. Immunother. 24 2001 392 407 (Pubitemid 33029909)
13. G.A. Rabinovich Immunosuppressive strategies that are mediated by tumor cells Annu. Rev. Immunol. 25 2007 267 296 (Pubitemid 46697910)
14. M.R. Shurin Intratumoral cytokines/chemokines/growth factors and tumor infiltrating dendritic cells: friends or enemies? Cancer Metastasis Rev. 25 2006 333 356 (Pubitemid 44922354)
15. + regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo Int. J. Cancer 121 2007 95 105 (Pubitemid 46753856)
16. M.R. Rezvany Dendritic cells in patients with non-progressive B-chronic lymphocytic leukaemia have a normal functional capability but abnormal cytokine pattern Br. J. Haematol. 115 2001 263 271
17. D. Gabrilovich Mechanisms and functional significance of tumour-induced dendritic-cell defects Nat. Rev. Immunol. 4 2004 941 952 (Pubitemid 39620069)
18. E. Gottfried Tumor-induced modulation of dendritic cell function Cytokine Growth Factor Rev. 19 2008 65 77 (Pubitemid 351200062)
19. A. Kolb-Maurer Listeria monocytogenes-infected human dendritic cells: uptake and host cell response Infect. Immun. 68 2000 3680 3688 (Pubitemid 30340474)
20. A. Kolb-Maurer Production of IL-12 and IL-18 in human dendritic cells upon infection by Listeria monocytogenes FEMS Immunol. Med. Microbiol. 35 2003 255 262 (Pubitemid 36324456)
21. M. Skoberne KBMA Listeria monocytogenes is an effective vector for DC-mediated induction of antitumor immunity J. Clin. Invest. 118 2008 3990 4001
22. + cytotoxic T cells with high cytolytic potential Cancer Immunol. Immunother. 59 2010 1185 1195
23. + T cell induction by dendritic cells matured with a clinical grade TLR-agonist in combination with IFN-gamma Int. J. Immunopathol. Pharmacol. 23 2010 35 50
24. V. Pulko TLR3-stimulated dendritic cells up-regulate B7-H1 expression and influence the magnitude of CD8 T cell responses to tumor vaccination J. Immunol. 183 2009 3634 3641
25. A.G. Jarnicki Attenuating regulatory T cell induction by TLR agonists through inhibition of p38 MAPK signaling in dendritic cells enhances their efficacy as vaccine adjuvants and cancer immunotherapeutics J. Immunol. 180 2008 3797 3806
26. I.S. Grewal, and R.A. Flavell CD40 and CD154 in cell-mediated immunity Annu. Rev. Immunol. 16 1998 111 135 (Pubitemid 28183361)
27. C. Mauri Therapeutic activity of agonistic monoclonal antibodies against CD40 in a chronic autoimmune inflammatory process Nat. Med. 6 2000 673 679 (Pubitemid 30398791)
28. C. Contin Membrane-anchored CD40 is processed by the tumor necrosis factor-alpha-converting enzyme. Implications for CD40 signaling J. Biol. Chem. 278 2003 32801 32809 (Pubitemid 37055721)
29. M. Tone Regulation of CD40 function by its isoforms generated through alternative splicing Proc. Natl. Acad. Sci. U. S. A. 98 2001 1751 1756 (Pubitemid 32165570)
30. B.A. Hanks Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-cell cancer vaccines in vivo Nat. Med. 11 2005 130 137 (Pubitemid 40321347)
31. H. Wei Cancer immunotherapy using in vitro genetically modified targeted dendritic cells Cancer Res. 68 2008 3854 3862
32. + T cells Cancer Gene Ther. 11 2004 135 147
33. S. Balkow Dendritic cell activation by combined exposure to anti-CD40 plus interleukin (IL)-12 and IL-18 efficiently stimulates anti-tumor immunity Exp. Dermatol. 18 2009 78 87
34. J. Borst CD27 and CD70 in T cell and B cell activation Curr. Opin. Immunol. 17 2005 275 281 (Pubitemid 40692662)
35. J. Hendriks CD27 is required for generation and long-term maintenance of T cell immunity Nat. Immunol. 1 2000 433 440
36. J. Hendriks CD27 promotes survival of activated T cells and complements CD28 in generation and establishment of the effector T cell pool J. Exp. Med. 198 2003 1369 1380 (Pubitemid 37392482)
37. + T cell priming J. Immunol. 177 2006 2969 2975 (Pubitemid 44277812)
38. P.J. Sanchez Combined TLR/CD40 stimulation mediates potent cellular immunity by regulating dendritic cell expression of CD70 in vivo J. Immunol. 178 2007 1564 1572 (Pubitemid 46154627)
39. + T cell responses by pathogens typically depends on CD70-mediated interactions with dendritic cells Eur. J. Immunol. 37 2007 716 728 (Pubitemid 46916938)
40. + T-cell immunity by immature dendritic cells in a vaccination setting Blood 113 2009 5167 5175
41. A. Bonehill Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L CD70 and constitutively active TLR4 encoding mRNA Mol. Ther. 16 2008 1170 1180 (Pubitemid 351737084)
42. J.M. Timmerman, and R. Levy Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine J. Immunol. 164 2000 4797 4803 (Pubitemid 30238082)
43. M. Durantez Tumor therapy in mice by using a tumor antigen linked to modulin peptides from Staphylococcus epidermidis Vaccine 28 2010 7146 7154
44. J. Shojaeian Mutual helper effect in copulsing of dendritic cells with 2 antigens: a novel approach for improvement of dendritic-based vaccine efficacy against tumors and infectious diseases simultaneously J. Immunother. 32 2009 325 332
45. +) T cell priming and tumor protection by enterotoxin B subunit-conjugated peptides targeted to dendritic cells Vaccine 27 2009 5252 5258
46. A. George-Chandy Cholera toxin B subunit as a carrier molecule promotes antigen presentation and increases CD40 and CD86 expression on antigen-presenting cells Infect. Immun. 69 2001 5716 5725 (Pubitemid 32786510)
47. K. Eriksson Cholera toxin and its B subunit promote dendritic cell vaccination with different influences on Th1 and Th2 development Infect. Immun. 71 2003 1740 1747 (Pubitemid 36368702)
48. K. Eriksson Coupling of antigen to cholera toxin for dendritic cell vaccination promotes the induction of MHC class I-restricted cytotoxic T cells and the rejection of a cognate antigen-expressing model tumor Eur. J. Immunol. 34 2004 1272 1281 (Pubitemid 39256006)
49. A.G. Chandy Therapeutic dendritic cell vaccination with Ag coupled to cholera toxin in combination with intratumoural CpG injection leads to complete tumour eradication in mice bearing HPV 16 expressing tumours Vaccine 25 2007 6037 6046 (Pubitemid 47077542)
50. + regulatory T-cell-mediated suppression Immunology 118 2006 240 249 (Pubitemid 43727429)
51. D.M. Sansom, and L.S. Walker The role of CD28 and cytotoxic T-lymphocyte antigen-4 (CTLA-4) in regulatory T-cell biology Immunol. Rev. 212 2006 131 148 (Pubitemid 44116705)
52. P. Waterhouse Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4 Science 270 1995 985 988
53. H. Ueda Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease Nature 423 2003 506 511 (Pubitemid 36648570)
54. F.J. Hsu, and M. Komarovskaya CTLA4 blockade maximizes antitumor T-cell activation by dendritic cells presenting idiotype protein or opsonized anti-CD20 antibody-coated lymphoma cells J. Immunother. 25 2002 455 468 (Pubitemid 35266311)
55. A. Ribas Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma Clin. Cancer Res. 15 2009 6267 6276
56. A.E. Pedersen Treatment of transplanted CT26 tumour with dendritic cell vaccine in combination with blockade of vascular endothelial growth factor receptor 2 and CTLA-4 Cancer Lett. 235 2006 229 238 (Pubitemid 44316484)
57. A. Saha, and S.K. Chatterjee Combination of CTL-associated antigen-4 blockade and depletion of CD25 regulatory T cells enhance tumour immunity of dendritic cell-based vaccine in a mouse model of colon cancer Scand. J. Immunol. 71 2010 70 82
58. H. Dong B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion Nat. Med. 5 1999 1365 1369
59. H. Tamura B7-H1 costimulation preferentially enhances CD28-independent T-helper cell function Blood 97 2001 1809 1816 (Pubitemid 32217250)
60. H. Dong Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion Nat. Med. 8 2002 793 800
61. Y. Agata Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes Int. Immunol. 8 1996 765 772 (Pubitemid 26148299)
62. T.J. Curiel Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity Nat. Med. 9 2003 562 567 (Pubitemid 36597102)
63. M. Jeddi-Tehrani Indoleamine 2,3-dioxygenase is expressed in the endometrium of cycling mice throughout the oestrous cycle J. Reprod. Immunol. 80 2009 41 48
64. A.L. Mellor, and D.H. Munn Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? Immunol Today 20 1999 469 473 (Pubitemid 29476077)
65. D.H. Munn Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase Science 297 2002 1867 1870 (Pubitemid 35024345)
66. D. Braun A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation Blood 106 2005 2375 2381 (Pubitemid 41510810)
67. M.S. von Bergwelt-Baildon CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition Blood 108 2006 228 237 (Pubitemid 43990633)
68. M. Wobser Dendritic cell based antitumor vaccination: impact of functional indoleamine 2,3-dioxygenase expression Cancer Immunol. Immunother. 56 2007 1017 1024 (Pubitemid 46675300)
69. X. Ou Enhancement of dendritic cell-tumor fusion vaccine potency by indoleamine-pyrrole 2,3-dioxygenase inhibitor, 1-MT J. Cancer Res. Clin. Oncol. 134 2008 525 533 (Pubitemid 351422606)
70. G.F. Flatekval, and M. Sioud Modulation of dendritic cell maturation and function with mono- and bifunctional small interfering RNAs targeting indoleamine 2,3-dioxygenase Immunology 128 Suppl 1 2009 e837 e848
71. M. Sioud Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization J. Mol. Biol. 348 2005 1079 1090 (Pubitemid 40602367)
72. V. Hornung Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7 Nat. Med. 11 2005 263 270 (Pubitemid 40460553)
73. A.D. Judge Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA Nat. Biotechnol. 23 2005 457 462 (Pubitemid 41724921)
74. S. Sakaguchi Immunologic self tolerance maintained by T-cell-mediated control of self-reactive T cells: implications for autoimmunity and tumor immunity Microbes Infect. 3 2001 911 918 (Pubitemid 32835305)
75. S. Onizuka Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody Cancer Res. 59 1999 3128 3133 (Pubitemid 29316012)
76. H. Jonuleit Immune regulation by regulatory T cells: implications for transplantation Transpl. Immunol. 11 2003 267 276 (Pubitemid 37120546)
77. C. Reis e Sousa Activation of dendritic cells: translating innate into adaptive immunity Curr. Opin. Immunol. 16 2004 21 25 (Pubitemid 38198114)
78. W. Maes DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma Neuro. Oncol. 11 2009 529 542
79. M.A. Morse Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines Blood 112 2008 610 618
80. D. Gabrilovich Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo Blood 92 1998 4150 4166 (Pubitemid 28544331)
81. B. Almand Clinical significance of defective dendritic cell differentiation in cancer Clin. Cancer Res. 6 2000 1755 1766 (Pubitemid 30305068)
82. B. Li Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy Clin. Cancer Res. 12 2006 6808 6816 (Pubitemid 44876851)
83. J.I. Youn Subsets of myeloid-derived suppressor cells in tumor-bearing mice J. Immunol. 181 2008 5791 5802
84. M. Habibi Radiofrequency thermal ablation of breast tumors combined with intralesional administration of IL-7 and IL-15 augments anti-tumor immune responses and inhibits tumor development and metastasis Breast Cancer Res. Treat. 114 2009 423 431
85. + T cells J. Clin. Invest. 116 2006 2777 2790 (Pubitemid 44511641)
86. D.I. Gabrilovich, and S. Nagaraj Myeloid-derived suppressor cells as regulators of the immune system Nat. Rev. Immunol. 9 2009 162 174
87. C.E. Hu Up-regulated myeloid-derived suppressor cell contributes to hepatocellular carcinoma development by impairing dendritic cell function Scand. J. Gastroenterol. 46 2011 156 164
88. J. Vincent 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity Cancer Res. 70 2010 3052 3061
89. J.D. Veltman COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma Celecoxib influences MDSC function BMC Cancer 10 2010 464
90. K. Ohkusu-Tsukada Adjuvant effects of formalin-inactivated HSV through activation of dendritic cells and inactivation of myeloid-derived suppressor cells in cancer immunotherapy Int. J. Cancer 128 2011 119 131
91. H.S. Kim Dendritic cell vaccine in addition to FOLFIRI regimen improve antitumor effects through the inhibition of immunosuppressive cells in murine colorectal cancer model Vaccine 28 2010 7787 7796
92. H.J. Ko Immunosuppressive myeloid-derived suppressor cells can be converted into immunogenic APCs with the help of activated NKT cells: an alternative cell-based antitumor vaccine J. Immunol. 182 2009 1818 1828
93. + immature myeloid cells into both suppressor macrophages and immunostimulatory dendritic cells Biomed. Res. 30 2009 7 15